adrenalin "martindale pharma" 0,1 mg/ml injektionsvæske, opløsning
ethypharm - adrenalintartrat - injektionsvæske, opløsning - 0,1 mg/ml
glycopyrronium bromide "martindale" 200 mikrogram/ml injektionsvæske, opløsning
ethypharm - glycopyrroniumbromid - injektionsvæske, opløsning - 200 mikrogram/ml
silocalm 2 mg/ml oral suspension
ethypharm - clobazam - oral suspension - 2 mg/ml
methadon "martindale pharma" 2 mg/ml oral opløsning
ethypharm - methadonhydrochlorid - oral opløsning - 2 mg/ml
silocalm 1 mg/ml oral suspension
ethypharm - clobazam - oral suspension - 1 mg/ml
suxamethonium chloride dihydrate "ethypharm" 50 mg/ml injektions-/infusionsvæske, opløsning
ethypharm - suxamethoniumchlorid (vandfrit) - injektions-/infusionsvæske, opløsning - 50 mg/ml
akynzeo
helsinn birex pharmaceuticals ltd - netupitant, palonosetron hydrochlorid - vomiting; neoplasms; nausea; cancer - antiemetika og antinauseants, - akynzeo er angivet i voksne til forebyggelse af akut og forsinket kvalme og opkastning i forbindelse med meget emetogenic cisplatin-baseret kemoterapi mod kræft. forebyggelse af akut og forsinket kvalme og opkastning i forbindelse med moderat emetogenic kræft kemoterapi.
combivent 2,5+0,5 mg/behold. inhalationsvæske til nebulisator, opløsning, enkeltdosisbeholder
paranova danmark a/s - ipratropiumbromidmonohydrat, salbutamolsulfat - inhalationsvæske til nebulisator, opløsning, enkeltdosisbeholder - 2,5+0,5 mg/behold.
combivent 2,5+0,5 mg/behold. inhalationsvæske til nebulisator, opløsning, enkeltdosisbeholder
boehringer ingelheim int. gmbh - ipratropiumbromidmonohydrat, salbutamolsulfat - inhalationsvæske til nebulisator, opløsning, enkeltdosisbeholder - 2,5+0,5 mg/behold.
brukinsa
beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastiske midler - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).